

Annexe 1

Références complémentaires de l'article de synthèse :

Rôle de la thrombospondine-1 dans le développement des maladies rénales

Naïke Bigé, Jean-Jacques Boffa, Fanny Lepeytre et Nasim Shweke

Med Sci (Paris) 2013 ; 29 (12) : 1131–1137

DOI : [10.1051/medsci/20132912017](https://doi.org/10.1051/medsci/20132912017)

Favier J, Germain S, Emmerich J, *et al.* Critical overexpression of thrombospondin 1 in chronic leg ischaemia. *J Pathol* 2005 ; 207 : 358-66.

Greenaway J, Henkin J, Lawler J, *et al.* ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. *Mol Cancer Ther* 2009 ; 8 : 64-74.

Hohenstein B, Daniel C, Hausknecht B, *et al.* Correlation of enhanced thrombospondin-1 expression, TGF-beta signalling and proteinuria in human type-2 diabetic nephropathy. *Nephrol Dial Transplant* 2008 ; 23 : 3880-7.

Isenberg JS, Hyodo F, Matsumoto K, *et al.* Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. *Blood* 2007 ; 109 : 1945-52.

Isenberg JS, Maxhimer JB, Powers P, *et al.* Treatment of liver ischemia-reperfusion injury by limiting thrombospondin-1/CD47 signaling. *Surgery* 2008 ; 144 : 752-61.

Isenberg JS, Ridnour LA, Dimitry J, *et al.* CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. *J Biol Chem* 2006 ; 281 : 26069-80.

Isenberg JS, Romeo MJ, Abu-Asab M, *et al.* Increasing survival of ischemic tissue by targeting CD47. *Circ Res* 2007 ; 100 : 712-20.

- Johansson U, Londei M. Ligation of CD47 during monocyte differentiation into dendritic cells results in reduced capacity for interleukin-12 production. *Scand J Immunol* 2004 ; 59 : 50-7.
- Klein J, Miravete M, Buffin-Meyer B, *et al.* La fibrose tubulo-interstitielle rénale - Menace fantôme ou dernière croisade ? *Med Sci (Paris)* ; 27 : 55-61.
- Lawler J, Sunday M, Thibert V, *et al.* Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. *J Clin Invest* 1998 ; 101 : 982-92.
- Li SS, Ivanoff A, Bergstrom SE, *et al.* T lymphocyte expression of thrombospondin-1 and adhesion to extracellular matrix components. *Eur J Immunol* 2002 ; 32 : 1069-79.
- Nor JE, Mitra RS, Sutorik MM, *et al.* Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. *J Vasc Res* 2000 ; 37 : 209-18.
- Poczatek MH, Hugo C, Darley-Usmar V, Murphy-Ullrich JE. Glucose stimulation of transforming growth factor-beta bioactivity in mesangial cells is mediated by thrombospondin-1. *Am J Pathol* 2000 ; 157 : 1353-63.
- Schultz-Cherry S, Chen H, Mosher DF, *et al.* Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. *J Biol Chem* 1995 ; 270 : 7304-10.
- Short SM, Derrien A, Narsimhan RP, *et al.* Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. *J Cell Biol* 2005 ; 168 : 643-53.
- Soumelis V, Volpe E. Différenciation des lymphocytes TH17 - Des souris et des hommes. *Med Sci (Paris)* 2008 ; 24 : 925-7.

Wang S, Wu Z, Sorenson CM, *et al.* Thrombospondin-1-deficient mice exhibit increased vascular density during retinal vascular development and are less sensitive to hyperoxia-mediated vessel obliteration. *Dev Dyn* 2003 ; 228 : 630-42.

Wang S, Wu Z, Sorenson CM, *et al.* Thrombospondin-1-deficient mice exhibit increased vascular density during retinal vascular development and are less sensitive to hyperoxia-mediated vessel obliteration. *Dev Dyn* 2003 ; 228 : 630-42.

Yee KO, Streit M, Hawighorst T, *et al.* Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta. *Am J Pathol* 2004 ; 165 : 541-52.

Zhang L, Yi H, Xia XP, Zhao Y. Transforming growth factor-beta: an important role in CD4+CD25+ regulatory T cells and immune tolerance. *Autoimmunity* 2006 ; 39 : 29-76.